Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-06-01
1999-11-02
Davenport, Avis M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 11, 530317, A61K 3800, A61K 3812, C07K 500, C07K 700
Patent
active
059770651
ABSTRACT:
A prodrug of the formula (I): ##STR1## where R.sup.1 is a group such that the compound R.sup.1 NH.sub.2 represents actinomycin D, doxorubicin, mitomycin C, or a nitrogen mustard of the formula (IV): ##STR2## a prodrug of the formula (II): ##STR3## where R.sup.2 is a group such that the compound R.sup.2 OH is a phenolic nitrogen mustard; and processes whereby the prodrugs shown above are made in which a prodrug precursor compound is reacted with 4-nitrobenzyl chloroformate under anhydrous conditions.
REFERENCES:
patent: 4472312 (1984-09-01), Anathasubramanian et al.
patent: 4617398 (1986-10-01), Bardos et al.
patent: 4680382 (1987-07-01), Sengupta
patent: 4868303 (1989-09-01), Takase et al.
McCalla, D.R., et al., "Genetics of Nitrofurazone Resistance in Escherichia coli", J. Bacteriol. vol. 133, pp. 10-16, (1978).
McCalla, D.R., . et al., Nitrofurazone-reducing enzymes in E. coli and their role n drug activation in vivo, Can. J. Microbiol., vol. 1, pp. 1484-1491, (1975).
Knox, R.J., et al., "The Nitroreductase Enzyme in Walker Cells That Activates 5-(Aziridin-1-YL)-2,4-Dinitrobenzamide (CB!1954) to 5-(Aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamidin is a form of NAD (P) H Dehydrogenase (Quinone) (EC.1.6.99.2)", Biochem. Pharmacol., vol. 37, pp. 4671-4677, (1988).
Tatsumi, K et al., "Studies on Oxygen-Insensitive Nitrofuran Reductase in Escheria coli/Br", J. Biochem., vol. 89, pp. 855-859. (1981).
Bryant, Christopher et al., "Cloning, Nucleotide Sequence, and Expression of the Nitroreductase Gene from Enterbacter cloacae", Journal of Biological Chemistry, vol. 266, No. 7, pp. 4126-4130 (Mar. 1991).
Bryant, D.W. et al., "Type I Nitroreductases of Escherichia coli", Canadian Journal of Microbiology, vol. 27, pp. 81-86 (1981).
Narai, Noriko et al., "A Comparative Study on 1-Nitro-pyrene and Nitrofurazone Reductases in Escherichia coli" J. Pharm. Dyn., vol. 7, pp. 407-413 (1984).
Doi, Takayoshi et al., "Properties of Nitrofuran Reductases from Escherichia coli B/r", Chem.Pharm.Bull., vol. 31, pp. 1105-1107 (1983).
Chemical Abstracts, vol. 95, Abstract No. 98201a (1981), Mikhailopulo, I.A. et al., "Synthesis of glycosides of nicotinamide and nicotinamide mononucleotide.".
Knox, Richard J., "A New Cytotoxic, DNA Interstrand Crosslinking Agent, 5-(Aziridin-1-YL)-4-Hydroxylamino-2-Nitrobenzamide, is Formed From 5-(Azirdin-1-YL)-2,4-in Walker Carcinoma Calls", Biochemical Pharmacology, vol. 37, No. 24, pp. 4661-4669 (1988).
Anlezark Gillian
Connors Thomas
Friedlos Frank
Jarman Michael
Knox Richard
Cancer Research Campaign - Technology Limited
Davenport Avis M.
Schneller John W.
LandOfFree
Bacterial nitroreductase for the reduction of CB1954 and analogu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bacterial nitroreductase for the reduction of CB1954 and analogu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bacterial nitroreductase for the reduction of CB1954 and analogu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2135504